Thierry Van Nieuwenhove, CEO of Quotient Sciences was recently featured in an industry podcast interview, sharing insights on the evolving role of CDMOs and the strategic advantages shaping the future of pharmaceutical development.
Recorded onsite during DCAT Week, the discussion reflects the ongoing industry dialogue around innovation, collaboration, and changing expectations placed on CDMO partners.
During the conversation, Mr. Van Nieuwenhove discussed key trends influencing the outsource market, including the growing demand for integrated development and manufacturing models, speed‑to‑clinic pressures, and how closer alignment across formulation, manufacturing, and clinical supply can help sponsors reduce risk and timelines.
The interview explored how Quotient Sciences’ differentiated approach supports more informed decision‑making earlier in development, particularly for complex molecules and accelerated programs. In highlighting emerging therapies such as GLP-1s, Mr. Van Nieuwenhove commented: "We are seeing a big trend with GLP-1s... Quotient Sciences has been able to work with nearly all GLP-1's out there in the market, helping with the formulation and [developing them] to the place where they are today."
Drawing on examples from across the pharmaceutical pipeline, Mr. Van Nieuwenhove continued to highlight why integration, scientific depth, and operational flexibility are becoming increasingly important for emerging and established pharma companies alike.
"This is where Quotient Sciences has the ability to help, getting faster to proof-of-concept than anyone else... As a small biotech or midsize biotech, you have the ability to go to your investors and raise more money, because you have demonstrated the ability to perform in Phase 1." he said.
The full episode, “This CDMO Has an Advantage No One Else Can Replicate,” is now available to watch on Youtube, as well as on Apple Podcasts and other podcast streaming services.